乳腺癌<sup>18</sup>F-FES雌激素受体PET技术和应用标准

杨忠毅; 许晓平; 王明伟; 张勇平; 杨建伟; 陈跃; 徐文贵; 李亚明; 章英剑; 宋少莉

doi:10.19401/j.cnki.1007-3639.2023.08.009

您当前的位置：

首页 >

文章列表页 >

乳腺癌¹⁸F-FES雌激素受体PET技术和应用标准

指南与共识 | 更新时间：2025-12-31

- 乳腺癌¹⁸F-FES雌激素受体PET技术和应用标准
- The specification and use of ¹⁸F-FES PET in breast cancer
- 中国癌症杂志 2023年33卷第8期页码：801-808
- 作者机构：
  
  1. 复旦大学附属肿瘤医院核医学科，复旦大学上海医学院肿瘤学系，复旦大学生物医学影像研究中心，上海分子影像探针工程技术研究中心，上海 200032
  2. 河南省肿瘤医院PET中心，河南郑州 450008
  3. 西南医科大学附属医院核医学科，四川泸州 646000
  4. 天津医科大学肿瘤医院分子影像及核医学诊疗科，天津 300060
  5. 中国医科大学附属第一医院核医学科，辽宁沈阳 110001
- 作者简介：
  
  [ "杨忠毅（ORCID: 0000-0001-6195-9942），博士，副主任医师，复旦大学附属肿瘤医院核医学科主任助理。" ]
  宋少莉（ORCID: 0000-0003-2544-7522），主任医师，教授，复旦大学附属肿瘤医院核医学科主任。
- 基金信息：
  
  上海市2022年度“科技创新行动计划”技术标准项目(22DZ2204500)
- DOI：10.19401/j.cnki.1007-3639.2023.08.009
  中图分类号： R737.9
- 收稿：2023-05-03，
  
  修回：2023-06-25，
  
  纸质出版：2023-08-30
- 稿件说明：
移动端阅览
杨忠毅, 许晓平, 王明伟, 等. 乳腺癌¹⁸F-FES雌激素受体PET技术和应用标准[J]. 中国癌症杂志, 2023,33(8):801-808.

Zhongyi YANG, Xiaoping XU, Mingwei WANG, et al. The specification and use of ¹⁸F-FES PET in breast cancer[J]. China Oncology, 2023, 33(8): 801-808.
杨忠毅, 许晓平, 王明伟, 等. 乳腺癌¹⁸F-FES雌激素受体PET技术和应用标准[J]. 中国癌症杂志, 2023,33(8):801-808. DOI： 10.19401/j.cnki.1007-3639.2023.08.009.

Zhongyi YANG, Xiaoping XU, Mingwei WANG, et al. The specification and use of ¹⁸F-FES PET in breast cancer[J]. China Oncology, 2023, 33(8): 801-808. DOI： 10.19401/j.cnki.1007-3639.2023.08.009.

摘要

约2/3的乳腺癌患者病灶为雌激素受体（estrogen receptor，ER）阳性。在活体内无创检测ER，并对其生物活性进行动态监测对作出个体化治疗决策至关重要。国内已有系列临床前和临床研究提示16α-

F-17β-氟雌二醇（16α-

F-17β-fluoroestradiol，

F-FES）正电子发射体层成像（positron emission tomography，PET）可用于ER表达分析，但尚缺乏相应技术规范。本技术标准由国内开展

F-FES PET研究与应用的专家共同执笔，参考自身经验及国内外该领域研究进展后共同商议制定。本技术标准介绍了

F-FES的合成方法和质量控制要求，给出其临床应用场景的推荐，并进行分级。此外，从显像前准备、显像流程、图像分析（正常生物分布、ER阳性和阴性的判定、病灶部位、影响因素、假阴性和假阳性、报告书写）等全流程系统、详尽给出了专家建议，指出了该显像技术的局限性，并对未来应用前景予以展望。该技术标准的制定旨在推动

F-FES PET技术在国内的规范化应用，实现报告解读一致、结果互认、指标可比，为乳腺癌精准诊疗提供重要的分子影像技术支撑。

Abstract

Estrogen receptor (ER) is overexpressed in approximately 2/3 of breast cancer patients’ lesions. Noninvasive detection of ER

in vivo

and dynamic monitoring of ER are crucial for individualized treatment decision-making. 16α-

F-17β-fluoroestradiol (

F-FES) positron emission tomography (PET) has been used in a variety of preclinical and clinical studies to detect ER expression. However

there is still a lack of technical specifications in China. This technical specification was jointly written by domestic experts who had experience of

F-FES PET imaging and was formed through consultation based on their own experience and research progress in this field both domestically and internationally. This technical specification introduced the synthesis method and quality control requirements of

F-FES

recommended its clinical application scenarios

and classified them. In addition

experts’ suggestions were provided throughout the entire process systemically and detailly

including

pre-imaging preparation

imaging process

image analysis (normal biological distribution

determination of ER positive and negative

lesion detection

influencing factors

false negative and false positive

report requirements)

and the limitations of this imaging technique were proposed. The future application prospects were also discussed. This specification aimed to promote the standardized application of

F-FES PET in China

achieve repeatability and comparability

and provide important molecular imaging technical support for accurate diagnosis and treatment of breast cancer.

关键词

Keywords

references

QIU H , CAO S , XU R . Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 [J ] . Cancer Commun (Lond) , 2021 , 41 ( 10 ): 1037 - 1048 .

HAYES D F , DOWSETT M , et al . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J ] . J Clin Oncol , 2010 , 28 ( 16 ): 2784 - 2795 . DOI: 10.1200/JCO.2009.25.6529 http://doi.org/10.1200/JCO.2009.25.6529

KALINOWSKI L , SAUNUS J M , MCCART REED A E , et al . Breast cancer heterogeneity in primary and metastatic disease [J ] . Adv Exp Med Biol , 2019 , 1152 : 75 - 104 . DOI: 10.1007/978-3-030-20301-6_6 http://doi.org/10.1007/978-3-030-20301-6_6

KIESEWETTER D O , KILBOURN M R , LANDVATTER S W , et al . Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats [J ] . J Nucl Med , 1984 , 25 ( 11 ): 1212 - 1221 .

ULANER G A . 16α-18F-fluoro-17β-fluoroestradiol (FES): clinical applications for patients with breast cancer [J ] . Semin Nucl Med , 2022 , 52 ( 5 ): 574 - 583 . DOI: 10.1053/j.semnuclmed.2022.03.002 http://doi.org/10.1053/j.semnuclmed.2022.03.002

MORI T , KASAMATSU S , MOSDZIANOWSKI C , et al . Automatic synthesis of 16 alpha-[(18)F]fluoro-17beta-estradiol using a cassette-type [(18)F]fluorodeoxyglucose synthesizer [J ] . Nucl Med Biol , 2006 , 33 ( 2 ): 281 - 286 .

张勇平 , 章英剑 , 王明伟 , 等 . 基于Explora GN/LC双模块的16α-[ 18 F ] 氟-17β-雌二醇全自动化合成 [J ] . 中华核医学杂志 , 2011 , 31 ( 3 ): 196 - 200 .

ZHANG Y P , ZHANG Y J , WANG M W , et al . Fully automated synthesis of 16α-[ 18 F ] fluoro-17B-estrogen using Explora GN/LC dual module [J ] . Chin J Nucl Med , 2011 , 31 ( 3 ): 196 - 200 .

袁慧瑜 , 许晓平 , 张勇平 , 等 . 18 F-雌二醇的质量控制研究 [J ] . 肿瘤影像学 2015 , 24 ( 3 ): 190 - 195 .

YUAN H Y , XU X P , ZHANG Y P , et al . Quality control of 18 F-fluoroestradiol for positron emission tomography [J ] . Oncoradiology , 2015 , 24 ( 3 ): 190 - 195 .

YANG Z Y , YUAN H Y , XU X P , et al . High specific activity is not optimal: 18 F-fluoroestradio positron emission tomography-computed tomography results in a breast cancer xenograft [J ] . J Label Compd Radiopharm , 2016 , 59 ( 13 ): 576 - 581 . DOI: 10.1002/jlcr.v59.13 http://doi.org/10.1002/jlcr.v59.13 http://doi.wiley.com/10.1002/jlcr.v59.13 http://doi.wiley.com/10.1002/jlcr.v59.13

YANG Z , SUN Y , XU X , et al . The assessment of estrogen receptor status and its intratumoral heterogeneity in patients with breast cancer by using 18 F-fluoroestradiol PET/CT [J ] . Clin Nucl Med , 2017 , 42 ( 6 ): 421 - 427 . DOI: 10.1097/RLU.0000000000001587 http://doi.org/10.1097/RLU.0000000000001587 https://journals.lww.com/00003072-201706000-00002 https://journals.lww.com/00003072-201706000-00002

VAN GEEL J J L , BOERS J , ELIAS S G , et al . Clinical validity of 16α-[ 18 F ] fluoro-17β-estradiol positron emission tomography/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer [J ] . J Clin Oncol , 2022 , 40 ( 31 ): 3642 - 3652 . DOI: 10.1200/JCO.22.00400 http://doi.org/10.1200/JCO.22.00400 https://ascopubs.org/doi/10.1200/JCO.22.00400 https://ascopubs.org/doi/10.1200/JCO.22.00400

KURLAND B F , WIGGINS J R , COCHE A , et al . Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16α- 18 F-fluoro-17β-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications [J ] . Oncologist , 2020 , 25 ( 10 ): 835 - 844 . DOI: 10.1634/theoncologist.2019-0967 http://doi.org/10.1634/theoncologist.2019-0967 https://academic.oup.com/oncolo/article/25/10/835/6443968 https://academic.oup.com/oncolo/article/25/10/835/6443968

CHAE S Y , AHN S H , KIM S B , et al . Diagnostic accuracy and safety of 16α-[ 18 F ] fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study [J ] . Lancet Oncol , 2019 , 20 ( 4 ): 546 - 555 . DOI: 10.1016/S1470-2045(18)30936-7 http://doi.org/10.1016/S1470-2045(18)30936-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204518309367 https://linkinghub.elsevier.com/retrieve/pii/S1470204518309367

LIU C , GONG C C , LIU S , et al . 18 F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with 18 F-FDG PET/CT [J ] . Oncologist , 2019 , 24 ( 12 ): e1277-e1285.

BOERS J , LOUDINI N , BRUNSCH C L , et al . Value of 18 F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study [J ] . J Nucl Med , 2021 , 62 ( 9 ): 1214 - 1220 . DOI: 10.2967/jnumed.120.256826 http://doi.org/10.2967/jnumed.120.256826 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.256826 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.256826

ULANER G A , JHAVERI K , CHANDARLAPATY S , et al . Head-to-head evaluation of 18 F-FES and 18 F-FDG PET/CT in metastatic invasive lobular breast cancer [J ] . J Nucl Med , 2021 , 62 ( 3 ): 326 - 331 . DOI: 10.2967/jnumed.120.247882 http://doi.org/10.2967/jnumed.120.247882 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.247882 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.247882

YANG Z Y XIE , Y Z , LIU C , et al . The clinical value of 18 F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies [J ] . Quant Imaging Med Surg , 2021 , 11 ( 9 ), 3956 - 3965 . DOI: 10.21037/qims http://doi.org/10.21037/qims http://qims.amegroups.com http://qims.amegroups.com

VAN KRUCHTEN M , GLAUDEMANS A W J M , DE VRIES E F J , et al . PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma [J ] . J Nucl Med , 2012 , 53 ( 2 ): 182 - 190 . DOI: 10.2967/jnumed.111.092734 http://doi.org/10.2967/jnumed.111.092734 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.111.092734 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.111.092734

LIU C , HU S , XU X , et al . Evaluation of tumour heterogeneity by 18 F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment [J ] . Breast Cancer Res , 2022 , 24 ( 1 ): 57 . DOI: 10.1186/s13058-022-01555-7 http://doi.org/10.1186/s13058-022-01555-7

XIE Y , DU X , ZHAO Y , et al . Chemotherapy shows a better efficacy than endocrine therapy in metastatic breast cancer patients with a heterogeneous estrogen receptor expression assessed by 18 F-FES PET [J ] . Cancers (Basel) , 2022 , 14 ( 14 ): 3531 . DOI: 10.3390/cancers14143531 http://doi.org/10.3390/cancers14143531 https://www.mdpi.com/2072-6694/14/14/3531 https://www.mdpi.com/2072-6694/14/14/3531

LIU C , XU X , YUAN H , et al . Dual tracers of 16α-[ 18 F ] fluoro-17β-estradiol and [ 18 F ] fluorodeoxyglucose for prediction of progression-free survival after fulvestrant therapy in patients with HR + /HER2 - metastatic breast cancer [J ] . Front Oncol , 2020 , 10 : 580277 . DOI: 10.3389/fonc.2020.580277 http://doi.org/10.3389/fonc.2020.580277 https://www.frontiersin.org/articles/10.3389/fonc.2020.580277/full https://www.frontiersin.org/articles/10.3389/fonc.2020.580277/full

HE M , LIU C , SHI Q , et al . The predictive value of early changes in 18 F-fluoroestradiol positro n emission tomography/computed tomography during fulvestrant 500 mg therapy in patients with estrogen receptor-positive metastatic breast cancer [J ] . Oncol , 2020 , 25 ( 11 ): 927 - 936 . DOI: 10.1634/theoncologist.2019-0561 http://doi.org/10.1634/theoncologist.2019-0561 https://academic.oup.com/oncolo/article/25/11/927/6443139 https://academic.oup.com/oncolo/article/25/11/927/6443139

GONG C C , YANG Z Y , SUN Y F , et al . A preliminary study of 18 F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel [J ] . Sci Rep , 2017 , 7 : 6584 . DOI: 10.1038/s41598-017-06903-8 http://doi.org/10.1038/s41598-017-06903-8

VAN KRUCHTEN M , DE VRIES E G , GLAUDEMANS A W , et al . Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer [J ] . Cancer Discov , 2015 , 5 ( 1 ): 72 - 81 . DOI: 10.1158/2159-8290.CD-14-0697 http://doi.org/10.1158/2159-8290.CD-14-0697

WANG Y B , AYRES K L , GOLDMAN D A , et al . 18 F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase Ⅰ trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials [J ] . Clin Cancer Res , 2017 , 23 ( 12 ): 3053 - 3060 . DOI: 10.1158/1078-0432.CCR-16-2197 http://doi.org/10.1158/1078-0432.CCR-16-2197 https://aacrjournals.org/clincancerres/article/23/12/3053/80307/18F-Fluoroestradiol-PET-CT-Measurement-of-Estrogen https://aacrjournals.org/clincancerres/article/23/12/3053/80307/18F-Fluoroestradiol-PET-CT-Measurement-of-Estrogen

LIN F I , GONZALEZ E M , KUMMAR S , et al . Utility of 18 F-fluoroestradiol ( 18 F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy [J ] . Eur J Nucl Med Mol Imaging , 2017 , 44 ( 3 ): 500 - 508 . DOI: 10.1007/s00259-016-3561-8 http://doi.org/10.1007/s00259-016-3561-8

JAGER A , DE VRIES E G E , DER HOUVEN VAN OORDT C W M , et al . A phase 1b study evaluating the effect of elacestrant treatment on estrogen re ceptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18 F-FES PET/CT imaging [J ] . Breast Cancer Res , 2020 , 22 ( 1 ): 97 . DOI: 10.1186/s13058-020-01333-3 http://doi.org/10.1186/s13058-020-01333-3

IQBAL R , YAQUB M , OPREA-LAGER D E , et al . Biodistribution of 18 F-FES in patients with metastatic ER + breast cancer undergoing treatment with rintodestrant (G1T48), a novel selective ER degrader [J ] . J Nucl Med , 2022 , 63 ( 5 ): 694 - 699 .

VENEMA C M , APOLLONIO G , HOSPERS G A , et al . Recommendations and technical aspects of 16α-[ 18 F ] fluoro-17β-estradiol PET to image the estrogen receptor in vivo : the groningen experience [J ] . Clin Nucl Med , 2016 , 41 ( 11 ): 844 - 851 . DOI: 10.1097/RLU.0000000000001347 http://doi.org/10.1097/RLU.0000000000001347 https://journals.lww.com/00003072-201611000-00002 https://journals.lww.com/00003072-201611000-00002

YOSHIDA Y , KIYONO Y , TSUJIKAWA T , et al . Additional value of 16α-[ 18 F ] fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on[ 18 F ] fluorodeoxyglucose PET [J ] . Eur J Nucl Med Mol Imaging , 2011 , 38 ( 10 ): 1824 - 1831 . DOI: 10.1007/s00259-011-1851-8 http://doi.org/10.1007/s00259-011-1851-8 http://link.springer.com/10.1007/s00259-011-1851-8 http://link.springer.com/10.1007/s00259-011-1851-8

VAN KRUCHTEN M , DE VRIES E F , ARTS H J , et al . Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α- 18 F-fluoro-17β-estradiol PET/CT [J ] . J Nucl Med , 2015 , 56 ( 1 ): 50 - 55 . DOI: 10.2967/jnumed.114.147579 http://doi.org/10.2967/jnumed.114.147579 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.114.147579 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.114.147579

ZHAO Z , YOSHIDA Y , KUROKAWA T , et al . 18 F-FES and 18 F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uter ine tumors: correlation with immunohistochemical analysis [J ] . J Nucl Med , 2013 , 54 ( 4 ): 499 - 506 . DOI: 10.2967/jnumed.112.113472 http://doi.org/10.2967/jnumed.112.113472 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.112.113472 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.112.113472

BOELLAARD R , DELGADO-BOLTON R , OYEN W J G , et al . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 [J ] . Eur J Nucl Med Mol Imaging , 2015 , 42 ( 2 ): 328 - 354 . DOI: 10.1007/s00259-014-2961-x http://doi.org/10.1007/s00259-014-2961-x http://link.springer.com/10.1007/s00259-014-2961-x http://link.springer.com/10.1007/s00259-014-2961-x

张建平 , 何思敏 , 顾丙新 , 等 . 基于小鼠全身动态PET扫描估算16α- 18 F-17β-雌二醇的人体内辐射剂量 [J ] . 中国癌症杂志 , 2016 , 26 ( 9 ): 770 - 776 . DOI: 10.19401/j.cnki.1007-3639.2016.09.008 http://doi.org/10.19401/j.cnki.1007-3639.2016.09.008

ZHANG J P , HE S M , GU B X , et al . Radiation dosimetry estimates of 18 F-fluoroestradiol based on whole-body PET imaging of mice [J ] . China Oncol , 2016 , 26 ( 9 ): 770 - 776 .

IQBAL R , MENKE-VAN DER HOUVEN VAN OORDT C W , OPREA-LAGER D E , et al . 18 F-FES uptake in the pituitary gland and white matter of the brain [J ] . Eur J Nucl Med Mol Imaging , 2021 , 48 ( 9 ): 3009 - 3010 . DOI: 10.1007/s00259-021-05281-8 http://doi.org/10.1007/s00259-021-05281-8

BOERS J , LOUDINI N , DE HAAS R J , et al . Analyzing the estrogen receptor status of liver metastases with [ 18 F ] -FES-PET in patients with breast cancer [J ] . Diagnostics (Basel) , 2021 , 11 ( 11 ): 2019 .

PETERSON L M , KURLAND B F , LINK J M , et al . Factors influencing the uptake of 18 F-fluoroestradiol in patients with estrogen receptor positive breast cancer [J ] . Nucl Med Biol , 2011 , 38 ( 7 ): 969 - 978 . DOI: 10.1016/j.nucmedbio.2011.03.002 http://doi.org/10.1016/j.nucmedbio.2011.03.002 https://linkinghub.elsevier.com/retrieve/pii/S0969805111000576 https://linkinghub.elsevier.com/retrieve/pii/S0969805111000576

YANG Z Y , SUN Y F , YAO Z F , et al . Increased 18 F-fluoroestradiol uptake in radiation pneumonia [J ] . Ann Nucl Med , 2013 , 27 ( 10 ): 931 - 934 . DOI: 10.1007/s12149-013-0761-1 http://doi.org/10.1007/s12149-013-0761-1 http://link.springer.com/10.1007/s12149-013-0761-1 http://link.springer.com/10.1007/s12149-013-0761-1

DEHDASHTI F , MORTIMER J E , SIEGEL B A , et al . Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays [J ] . J Nucl Med , 1995 , 36 ( 10 ): 1766 - 1774 .

GEMIGNANI M L , PATIL S , SESHAN V E , et al . Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer [J ] . J Nucl Med , 2013 , 54 ( 10 ): 1697 - 1702 . DOI: 10.2967/jnumed.112.113373 http://doi.org/10.2967/jnumed.112.113373 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.112.113373 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.112.113373

MCGUIRE A H , DEHDASHTI F , SIEGEL B A , et al . Positron tomographic assessment of 16 alpha-[ 18 F ] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma [J ] . J Nucl Med , 1991 , 32 ( 8 ): 1526 - 1531 .

浏览量

2085

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

中国年轻女性乳腺癌发病、死亡近30年的变迁情况及趋势研究

miR-193a-3p通过靶向TRIM14对乳腺癌干细胞迁移和侵袭的影响

乳腺癌新辅助治疗后的腋窝管理及前哨淋巴结诊治的优化

乳腺癌18F-FES雌激素受体PET技术和应用标准

The specification and use of 18F-FES PET in breast cancer

DOI：10.19401/j.cnki.1007-3639.2023.08.009

摘要

Abstract

关键词

Keywords

references

乳腺癌¹⁸F-FES雌激素受体PET技术和应用标准

The specification and use of ¹⁸F-FES PET in breast cancer